Journal List > J Lung Cancer > v.8(2) > 1050708

J Lung Cancer. 2009 Dec;8(2):67-77. Korean.
Published online December 31, 2009.  https://doi.org/10.6058/jlc.2009.8.2.67
©2009 Korean Association for the Study of Lung Cancer
Biomarkers for Lung Cancer
Sei Hoon Yang, M.D., Ph.D.
Department of Internal Medicine, Wonkwang University College of Medicine, Iksan, Korea.

Address for correspondence: Sei Hoon Yang, M.D., Ph.D. Department of Internal Medicine, Wonkwang University Hospital, 344-2, Shinyong-dong, Iksan 570-711, Korea. Tel: 82-63-859-2582, Fax: 82-63-855-2025, Email: yshpul@wonkwang.ac.kr
Received November 13, 2009; Accepted November 20, 2009.

Abstract

Over the last decade, intense interest has been focused on discovery of biomarkers and their clinical uses. Lung cancer biomarker discovery has particular eminence in this field due to its anticipated critical role in risk stratification, early detection, treatment selection, prognostication, and monitoring for recurrence of cancer. Significant progress has been made in our understanding of the steps involved in lung carcinogenesis and in development of novel technologies for biomarker discovery. The most active areas of research have been in promoter hypermethylation, proteomics, and genomics. Many investigators have adopted panels of serum biomarkers in an attempt to increase sensitivity. Markers for identification of lung cancer patients who may benefit from targeted therapy have been developed more rapidly. Development of targeted lung cancer therapy has engendered interest in markers for identification of optimal candidates for these therapies. Despite extensive study to date, few have turned out to be useful in the clinic. Even those used in the clinic do not show enough sensitivity, specificity, and reproducibility for general use. All biomarkers identified so far must be validated in larger clinical cohorts.

Keywords: Biological markers; Lung neoplasms

Tables


Table 1
Potential Biomarkers from Specimens of Human Various Cancers
Click for larger image


Table 2
Characteristics of the Ideal Tumor Marker
Click for larger image


Table 3
Protein-Based Biomarkers in Detection of Lung Cancer: Currently Available
Click for larger image


Table 4
Gene-Based Biomarkers in Detection of Lung Cancer: Potential
Click for larger image


Table 5
Protein-Based Biomarkers for the Detection of Lung Cancer: Potential
Click for larger image

Notes

This work was supported by Wonkwang Clinical Medical Research Center Grant in 2006 (WCMRC-2006-01).

This paper was reported to Lung Cancer Symposium 2009 in the Korean Academy for Tuberculosis and Respiratory Diseases.

References
1. Kim YC, Kwon YS, Oh IJ, et al. National survey of lung cancer in Korea, 2005. J Lung Cancer 2007;6:67–73.
2. Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med 2005;352:2714–2720.
3. Dalton WS, Friend SH. Cancer biomarkers: an invitation to the table. Science 2006;312:1165–1168.
4. Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual frame-work. Clin Pharmacol Ther 2001;69:89–95.
5. Oh P, Li Y, Yu J, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004;429:629–635.
6. Park HJ, Kim BG, Lee SJ, et al. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res 2008;7:1138–1150.
7. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Collaborators from 14 Countries. World Health Organization. In: International histological classification of tumors. Histological typing of lung and pleural tumors. 3rd ed. New York: Springer-Verlag; 1999.
8. Greenberg AK, Yee H, Rom WN. Preneoplastic lesions of the lung. Respir Res 2002;3:20.
9. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707–717.
10. Brabender J, Metzger R, Salonga D, et al. Comprehensive expression analysis of retinoic acid receptors and retinoid X receptors in non-small cell lung cancer: implications for tumor development and prognosis. Carcinogenesis 2005;26:525–530.
11. Ardizzoni A, Cafferata MA, Tiseo M, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006;107:2842–2849.
12. Okada M, Nishio W, Sakamoto T, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004;78:216–221.
13. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1–41.
14. Haam SJ, Kim GD, Cho SH, Lee DY. Clinical effectiveness of tumor markers (CEA, NSE, Cyfra 21-1) in completely resected non-small cell lung cancer. J Lung Cancer 2006;5:75–83.
15. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931–1937.
16. Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003;41:311–320.
17. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003;39:131–138.
18. Molina R, Filella X, Auge JM. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004;37:505–511.
19. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216–5222.
20. Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 2006;12:3078–3084.
21. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529–540.
22. Xue X, Zhu YM, Woll PJ. Circulating DNA and lung cancer. Ann N Y Acad Sci 2006;1075:154–164.
23. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659–1665.
24. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11–20.
25. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689–2692.
26. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845–856.
27. Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 2003;39:36s–44s.
28. Chung GT, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbitts PH. Sequential molecular genetic changes in lung cancer development. Oncogene 1995;11:2591–2598.
29. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 1995;87:1224–1229.
30. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52:2665S–2669S.
31. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903–2906.
32. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998;4:1609–1618.
33. Gazzeri S, Brambilla E, Caron de Fromentel C, et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994;58:24–32.
34. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
35. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006;8:30–38.
36. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891–11896.
37. Chaussade L, Eymin B, Brambilla E, Gazzeri S. Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15 (INK4b) methylation status. Oncogene 2001;20:6587–6596.
38. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67–70.
39. Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K. Hypermethylation of p16 (INK4a) and p15 (INK4b) genes in non-small cell lung cancer. Int J Oncol 2001;19:277–281.
40. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954–5958.
41. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303–1307.
42. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249–255.
43. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371–375.
44. Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003;193:207–216.
45. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005;11:6505–6511.
46. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338–3344.
47. Marsit CJ, Okpukpara C, Danaee H, Kelsey KT. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog 2005;44:146–150.
48. Yano M, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer 2005;113:59–66.
49. Zhang Z, Tan S, Zhang L. Prognostic value of apoptosis-associated speck-like protein containing a CARD gene promoter methylation in resectable non-small-cell lung cancer. Clin Lung Cancer 2006;8:62–65.
50. Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar AF. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004;100:1472–1477.
51. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66:4049–4054.
52. Grote HJ, Schmiemann V, Geddert H, et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 2006;108:129–134.
53. Ehrich M, Field JK, Liloglou T, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006;66:10911–10918.
54. Lee SH, Kim YT, Sung SW, Kim JH. Correlation between aberrant promoter hypermethylation of CpG islands and the clinical outcome of non-small cell lung cancer after curative resection. J Lung Cancer 2004;3:77–85.
55. Yoon KA, Hwangbo B, Kim IJ, et al. Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis 2006;27:2217–2222.
56. Omenn GS. Strategies for plasma proteomic profiling of cancers. Proteomics 2006;6:5662–5673.
57. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971–983.
58. Miura N, Nakamura H, Sato R, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 2006;97:1366–1373.
59. Lin X, Gu J, Lu C, Spitz MR, Wu X. Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:5720–5725.
60. El-Zein RA, Schabath MB, Etzel CJ, Lopez MS, Franklin JD, Spitz MR. Cytokinesis-blocked micronucleus assay as a novel biomarker for lung cancer risk. Cancer Res 2006;66:6449–6456.
61. Jakupciak JP, Wang W, Markowitz ME, et al. Mitochondrial DNA as a cancer biomarker. J Mol Diagn 2005;7:258–267.
62. McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr Cancer Ther 2006;5:30–39.
63. Poli D, Carbognani P, Corradi M, et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005;6:71.
64. Wang YC, Hsu HS, Chen TP, Chen JT. Molecular diagnostic markers for lung cancer in sputum and plasma. Ann N Y Acad Sci 2006;1075:179–184.
65. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007;13:249–255.